For the MOSAIC project team, the AIDS 2022 conference set the stage for embracing the introduction of new biomedical HIV prevention products and generating evidence on how to support choice and effective use. We attended the conference virtually and took away three key messages that resonate with our work on MOSAIC.
Continue Reading
The future of HIV prevention is here. Injectable cabotegravir (CAB) is the most effective, longest-acting option for avoiding the virus. Until now, pre-exposure prophylaxis (or PrEP) medicine taken to prevent HIV has only been available as an oral pill that must be taken daily. CAB needs to be injected only once every two months.
Continue Reading
This workshop will explore what is needed to ensure that introductory research and programs are strategically designed, user-centered, and appropriately resourced to support successful rollout of CAB PrEP.
Continue Reading
As we move toward a multi-product HIV prevention market, adolescent girls and young women must be empowered to choose an HIV prevention product that meets their needs.
Continue Reading
When countries introduce novel HIV prevention products, such as the PrEP ring and injectable CAB PrEP, how will women decide which product to use, and what will influence those decisions?
Continue Reading
Today, we observe International Women’s Day, a day to celebrate the many achievements of women around the globe.
Continue Reading
In this webinar, we explore ongoing and completed research on CAB PrEP, learn about the recently released FDA guidance, and hear from a panel of implementers and policymakers on what is needed to advance introduction of this new HIV prevention product.
Continue Reading